Total number of shares and voting rights in Zealand Pharma at October 31, 2022
Zealand Pharma A/S announces its total number of shares and voting rights as of October 31, 2022, in compliance with the Danish Capital Markets Act. Following a recent increase in share capital due to a private placement of 4,975,000 new shares, Zealand now has a total of 51,513,186 shares, which equals the same number for voting rights and share capital. This reflects Zealand's ongoing focus on developing innovative peptide-based medicines, with several drug candidates advancing in clinical development.
- Total shares and voting rights stand at 51,513,186, indicating a stable capital structure following the recent share issuance.
- None.
Company announcement – No. 48 / 2022
Total number of shares and voting rights in Zealand Pharma at October 31, 2022
Copenhagen, Denmark and Boston, MA, U.S. October 31, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.
In Company announcement No. 44/2022 from October 4, 2022, Zealand announced an increase in share capital due to a directed issue and private placement of 4,975,000 new ordinary shares. Following this announcement, the table below lists the total number of shares and voting rights in Zealand up to and including October 31, 2022.
| Date | Number of shares (nominal value of DKK 1 each) | Share capital (nominal value in DKK) | Number of voting rights |
| October 31, 2022 | 51,513,186 | 51,513,186 | 51,513,186 |
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development and partnerships with a number of blue-chip pharma companies as well as commercial partnerships for its marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. that includes Boston. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.
Contact:
| Anna Krassowska, PhD Vice President, Investor Relations & Corporate Communications Zealand Pharma Email: ank@zealandpharma.com |
FAQ
What is the total number of shares for Zealand Pharma as of October 31, 2022?
How many new shares were issued in Zealand Pharma's recent placement?
What is the significance of the total shares and voting rights announcement made by Zealand Pharma?
